HomeREGN34 • BVMF
add
Regeneron Pharmaceuticals Inc BDR
Previous close
R$65.66
Year range
R$44.73 - R$73.33
Market cap
79.81B USD
Avg Volume
990.00
P/E ratio
-
Dividend yield
-
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 3.88B | 2.51% |
Operating expense | 775.00M | -2.17% |
Net income | 844.60M | -7.97% |
Net profit margin | 21.74 | -10.24% |
Earnings per share | 11.44 | -5.22% |
EBITDA | 1.04B | -8.93% |
Effective tax rate | 19.08% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 8.61B | -4.52% |
Total assets | 40.56B | 7.41% |
Total liabilities | 9.30B | 10.66% |
Total equity | 31.26B | — |
Shares outstanding | 102.62M | — |
Price to book | 0.22 | — |
Return on assets | 5.57% | — |
Return on capital | 6.57% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | 844.60M | -7.97% |
Cash from operations | 1.17B | -7.29% |
Cash from investing | 220.30M | -37.16% |
Cash from financing | -780.10M | 31.30% |
Net change in cash | 610.60M | 27.95% |
Free cash flow | 202.00M | -48.90% |
About
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap. Wikipedia
Founded
1988
Headquarters
Website
Employees
15,410
